U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease
April 8 (Reuters) - The U.S. Food and Drug Administration (FDA) declined to approve Supernus Pharmaceuticals' SUPN.O drug-device combination to treat movement-related symptoms of Parkinson's disease, the drugmaker said on Monday. (Reporting by Puyaan Singh in Bengaluru; Editing by Shinjini Ganguli) ((Puyaan.Singh@thomsonreuters.com;))
Recent news on Kyowa Kirin
See all newsFactbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Factbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Brief: Kyowa Kirin Announces Agreement With US Administration To Reduce Treatment Costs For Americans
Table: Kyowa Kirin 6-MTH group results (IFRS)
Brief: Kyowa Kirin Says European Commission Approves Crysvita For Infants With X-Linked Hypophosphataemia